24 results
424B5
ANVS
Annovis Bio Inc
1 Nov 23
Prospectus supplement for primary offering
12:24pm
to the impact of the COVID-19 pandemic;
announcement or progression of geopolitical events (including in relation to the conflict between Russia
424B5
ANVS
Annovis Bio Inc
30 Oct 23
Prospectus supplement for primary offering
5:27pm
compliance, and product recalls;
general economic, industry and market conditions, including but not limited to the impact of the COVID-19 pandemic
8-K
qtp9xfgi
12 Nov 21
Annovis Bio Presented at the 14th Clinical Trials on Alzheimer’s Disease Conference
10:32am
8-K
xsrejuyw4s2
5 Oct 21
Annovis Bio Announces Positive Phase 2 Efficacy Data for the Treatment of Parkinson’s Disease
8:16am
8-K
EX-99.1
k1paik
11 Aug 21
Regulation FD Disclosure
8:32am
8-K
uqjjqrorsqdb659en
11 Aug 21
Regulation FD Disclosure
8:32am
424B4
exyeyci560
24 May 21
Prospectus supplement with pricing info
5:23pm
424B4
qljgc6i7xmfl fet
21 May 21
Prospectus supplement with pricing info
5:00pm